Detalhe da pesquisa
1.
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Lancet
; 402(10398): 291-303, 2023 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37285865
2.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Oncologist
; 2024 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394384
3.
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Lancet
; 399(10336): 1695-1707, 2022 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35405085
4.
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis.
Future Oncol
; 19(12): 819-828, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37222151
5.
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
N Engl J Med
; 381(26): 2506-2518, 2019 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31566937
6.
Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer.
Future Oncol
; 18(27): 2979-2986, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35950899
7.
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design.
Future Oncol
; 18(4): 425-436, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35080190
8.
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.
Future Oncol
; 18(10): 1185-1198, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35034502
9.
Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial.
Cancer Immunol Immunother
; 70(12): 3679-3692, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34351436
10.
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
Radiology
; 299(1): 109-119, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33497314
11.
Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies.
Curr Opin Urol
; 31(3): 242-248, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33742977
12.
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Lancet Oncol
; 21(11): 1513-1525, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32926841
13.
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.
BMC Cancer
; 20(1): 99, 2020 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32024476
14.
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Int J Cancer
; 145(7): 1970-1981, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30807643
15.
Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
Oncologist
; 24(5): 680-687, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30126859
16.
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
BMC Cancer
; 19(1): 12, 2019 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30612558
17.
An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
BJU Int
; 123(3): 456-464, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30098093
18.
Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
Curr Oncol Rep
; 21(5): 42, 2019 03 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30919167
19.
Radium-223 international early access program: results from the Spanish subset.
Future Oncol
; 14(1): 41-50, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29232987
20.
Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.
Prostate
; 77(1): 114-120, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27800640